Commissioner Olivér Várhelyi addressed the Brain Innovation Days 2025 in Brussels on October 14, emphasizing brain health as a strategic priority for Europe’s future. Várhelyi painted the brain not only as central to physical and mental health but also as the wellspring of innovation capable of tackling chronic neurological disorders like dementia, which currently affects nearly 8 million Europeans.
\nFunding and Innovation Strategy
The commissioner highlighted concrete initiatives under the EU4Health programme supporting projects focused on brain health, such as improving prevention, early detection of dementia, and digital innovations reducing stigma and health disparities. These initiatives are anchored within the European Health Data Space, aiming to bolster health data infrastructures dedicated to brain research.
Notably, Várhelyi announced the upcoming Biotech Act, set for presentation by year's end. This legislation aims to simplify biotechnology regulations, enhance research funding, facilitate investment, and ease market access for innovative products. The Biotech Act intends to foster cross-sector collaboration among pharmaceuticals, medical devices, AI, and big data industries, potentially accelerating new therapies and patient-centered care models.
\nRegulatory Reform and Financial Commitments
In parallel, the commissioner expressed plans to reform pharmaceutical legislation and medical devices regulation, aiming for more predictability, flexibility, and support for digital innovation. These regulatory reforms seek to address the gap in effective treatments for many brain conditions.
Financially, Várhelyi pointed to the upcoming Multiannual Financial Framework, proposing over €22 billion for competitiveness in health, biotech, agriculture, and bioeconomy policy areas via the European Competitiveness Fund. Additionally, €20 billion from Horizon Europe would support collaborative research.
\nStakeholder Impacts
The proposals indicate a shift toward increasing EU regulatory influence and investment in brain-related biotech innovation, contrasting with potential national sovereignty preferences. Biotech firms stand to benefit from reduced administrative barriers and increased funding, enhancing competitiveness and innovation. Healthcare providers and patients may gain from improved diagnostics and treatment options, but could face challenges adapting to new technologies and care models. National health authorities may need to coordinate with strengthened EU-level frameworks, adjusting to revamped regulations and funding mechanisms. Civil society actors focusing on patient advocacy might welcome the patient-centered approach but will likely monitor implementation closely.
This speech positions brain health innovation as a cross-sectoral priority, with concrete legislative and financial proposals aiming at strengthening the EU’s role in health innovation without yet specifying detailed deadlines or budget breakdowns for each initiative.